Prominent plasmacytosis following intravenous immunoglobulin correlates with clinical improvement in Guillain-Barré syndrome.
BACKGROUND: High doses of pooled polyclonal IgG are commonly used to treat numerous autoimmune diseases. Their mode of action nevertheless remains only partially explained. At the same time, until now, no early biological marker has been able to predict their efficacy. METHODOLOGY/PRINCIPAL FINDINGS...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2008-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC2362102?pdf=render |